ASLAN Pharmaceuticals, a clinical-stage biotech developing cancer therapies using the HER pathway, filed on Monday with the SEC to raise up to $86 million in a US initial public offering.
The company is listed on the Taipei Exchange (TPEx: 6497) with a market cap of $193 million.
The Singapore-based company was founded in 2010 and plans to list on the Nasdaq under the symbol ASLN. ASLAN Pharmaceuticals filed confidentially on December 20, 2017. Leerink Partners and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
